The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The rationale behind exploring the dual-antigen-targeting CAR T-cell construct ADZ0120 in myeloma
In this interview, Binod Dhakal, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the rationale and benefits of targeting both BCMA and CD19 in multiple myeloma (MM) with the dual-antigen-targeting CAR T-cell construct AZD0120. Dr Dhakal highlights that this approach could enhance the durability of CAR-T responses and reduce manufacturing time. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
